Reuters
@Reuters·4.2M subscribers·86.9K videos
Lilly forecasts weak sales of weight-loss drug, shares slump | REUTERS
Posted
January 14, 2025
Views
750
Likes
13
Engagement
1.73%
Search the Record
IndexedEvery word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
YouTube Description
as posted by the channelEli Lilly's stock dropped 8% after forecasting fourth-quarter sales of its weight-loss drug Zepbound below Wall Street estimates, marking the second sales disappointment since its late 2023 launch.
#News #elililly #shares #healthcare #zepbound #Reuters #Newsfeed
Read the story here
👉 Subscribe
Keep up with the latest news from around the world
Follow Reuters on Facebook
Follow Reuters on Twitter
Follow Reuters on Instagram
Links & Promotions
Guests & Subjects Covered
Eli Lilly'sWall StreetReuters Newsfeed ReadSubscribe KeepFollow ReutersFacebook Follow ReutersTwitter Follow Reuters
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.